Psychiatric issues in solid organ transplantation.
The identification and treatment of psychiatric comorbidity in patients undergoing solid organ transplantation present a unique opportunity for psychiatric involvement in the care of medically complex patients. The burden of psychiatric illness in patients awaiting transplant and following transplant is significant and associated with potential morbidity and mortality. Possibilities for psychiatric liaison with our colleagues in transplant medicine and surgery start with the comprehensive psychiatric evaluation that is often performed with potential organ recipients and donors. The vital role of the psychiatrist continues following transplantation, as adjustment is often a stressful experience with associated psychiatric comorbidity. The treatment of psychiatric illness in patients following transplantation requires an understanding of the immunosuppressant medications that patients may be taking, coupled with an awareness of the associated risks of adverse effects and drug-drug interactions.
Heinrich
Thomas W
TW
Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA. theinric@mcw.edu
Marcangelo
Michael
M
D015897:Comorbidity; D003299:Cooperative Behavior; D004347:Drug Interactions; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D033183:Interdisciplinary Communication; D019520:Living Donors / Q000523:psychology; D001523:Mental Disorders / Q000175:diagnosis / Q000523:psychology* / Q000628:therapy; D016377:Organ Transplantation / Q000523:psychology*; D010348:Patient Care Team; D011182:Postoperative Care; D011570:Psychiatry; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011788:Quality of Life / Q000523:psychology; D012017:Referral and Consultation; D014019:Tissue Donors / Q000523:psychology*
D007166:Immunosuppressive Agents; D011619:Psychotropic Drugs